BAFFR-CAR T cells not checked

PeproMene Bio, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
2 active
2 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“First-in-human trial examining the safety and preliminary efficacy of BAFFR-CAR T cells in participants with r/r B-ALL”In the company’s words, NCT04690595 on ClinicalTrials.gov
Tested for
Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Main trialPhase 1
“A Phase 1 Study Evaluating BAFFR-targeting CAR T Cells for Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia”In the company’s words, NCT04690595 on ClinicalTrials.gov

Other drugs for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

All 266 drugs for Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 1Active, not recruiting 18 Nov 2026 BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
Phase 1Recruiting 13 Jul 2027 BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow BAFFR-CAR T cells

Following is part of Solo: you see every change to BAFFR-CAR T cells the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in